Masimo (MASI)

Masimo’s product portfolio includes pulse oximetry and other noninvasive monitoring technologies, along with hospital automation, connectivity, remote monitoring, and related consumables and accessories. The company is widely associated with Signal Extraction Technology, which is used in pulse oximetry systems intended to deliver accurate readings during patient motion and low-perfusion conditions. Its broader platform includes products for operating rooms, intensive care units, emergency departments, general wards, and post-acute environments.

The company sells to a wide range of healthcare customers, including hospitals, emergency medical service providers, physician offices, home care organizations, and veterinary practices. It also participates in consumer health, reflecting a broader push by medical device companies to extend monitoring beyond traditional clinical settings and into the home.

Masimo’s business model combines equipment placements, technology licensing, sensors, software, and service relationships. Its competitive position rests on clinical validation, hospital adoption, integration with care workflows, and the recurring demand for monitoring consumables. As a listed healthcare technology company, MASI is influenced by hospital capital spending, procedure volumes, reimbursement trends, regulatory requirements, and the pace at which health systems adopt connected monitoring and automation tools.